Announcement on Receiving Performance Compensation for Foreign Investment of Subsidiators
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2018-034
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Announcement of Zhejiang Jianfeng Group Co., Ltd.
on Performance Compensation Received by Subsidiaries for Foreign Investment
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Basic Information on 1. Performance Commitment
On February 28, 2017, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a subsidiary of the Company, and Guilin Shangyuan Plant Products Co., Ltd. (hereinafter referred to as "Guilin Shangyuan") and Beijing Huibaoyuan Enterprise Management Co., Ltd. (hereinafter referred to: beihui Management) and Beijing Huibaoyuan Biotechnology Co., Ltd. (hereinafter referred to as: Beihui Biotechnology) signed the "Agreement on Capital Increase and Equity Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." (hereinafter referred to as: "Master Agreement"), "Performance Commitment Compensation Agreement", agreed that under the premise of meeting the investment conditions of each period, Jianfeng Pharmaceutical intends to increase capital and transfer equity, investment in Beihui Biology in stages.
According to the Performance Commitment Compensation Agreement, Beihui Management and Guilin Shangyuan have made commitments to the target net profit of Beihui Biology in each year of the compensation period. If the actual net profit of Beihui Biology in a certain year is lower than the target net profit promised in the current period, Beihui Management and Guilin Shangyuan will compensate Jianfeng Pharmaceutical in the form of cash or shares. For details, please refer to the announcement
-Pro 2017-003"Announcement on Foreign Investment of Subsidiators" published by the company in the designated information disclosure media "shanghai securities news", "china securities journal" and the website of Shanghai Stock Exchange (www.sse.com.cn ) on March 1, 2017.
2. Performance Commitment Compensation(I) Jianfeng Pharmaceutical has completed the first phase of investment in 80 million yuan. Beihui Biology's registered capital has increased from 80 million yuan to 100 million yuan, of which Jianfeng Pharmaceutical holds 20 million shares, with a shareholding ratio of 20%.
(II) Beihui Biology's holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd.'s newly-built production base located in the "China-Malaysia Qinzhou Industrial Park" is in the GMP certification stage and has not yet been fully put into production. Due to large investment and other reasons, Beihui Biology suffered a net profit loss attributable to the owner of the parent company in 2017. According to CAC Special Zi [2018] No. 0955 "Verification Report on Performance Commitments of Beijing Huibaoyuan Biotechnology Co., Ltd." issued by China Certified Public Accountants (Special General Partnership), Beihui Biotechnology's net profit attributable to the owner of the parent company in 2017 was -37.3434 million yuan, and failed to fulfill its performance promise of "achieving break-even in 2017. Beihui Management and Guilin Shangyuan shall pay 7.4687 million yuan as compensation for 2017 annual performance to Jianfeng Pharmaceutical.
The (III) Commitment Party decided that Beihui Management would choose shares to compensate Jianfeng Pharmaceutical. According to the agreement of the Performance Commitment Compensation Agreement, Beihui Management would transfer its 1,867,169 shares of Beihui Biology to Jianfeng Pharmaceutical at the price (4 yuan/share) of the latest capital increase from Jianfeng Pharmaceutical to Beihui Biology, and compensate Jianfeng Pharmaceutical with the obtained 7.4687 million yuan equity transfer.
On December 25, 2018, Beihui Bio received the "Filing Notice" from the registration agency, and has completed the registration procedures for the change of the above-mentioned shares. Peak Pharmaceutical has also received the compensation of 7.4687 million yuan paid by Beihui Management. So far, Beihui Management has fulfilled the agreement of the Performance Commitment Compensation Agreement and completed the performance compensation for 2017.
As of the announcement date, Peak Pharmaceuticals holds a total of 21,867,169 shares of Beihui Bio, with a shareholding ratio of 21.87.
is hereby announcedZhejiang Jianfeng Group Co., Ltd. Board of Directors
December 27, 2018
More information
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-31
Jinhua chain pharmacy big "physical examination" peak pharmacy got an "A"
Jinhua City Market Supervision Bureau recently announced the results of drug quality credit rating of drug retail chain enterprises in the city, and Jianfeng Pharmacy was rated as A in this "physical examination. According to the spirit of the document "Implementation Plan for Drug Quality Credit Classification Management of Jinhua Drug Trading Enterprises" and in accordance with relevant evaluation standards, Jinhua Market Supervision Bureau evaluated the 2019 drug quality credit rating of 34 drug retail chain enterprises (headquarters) in the city that met the evaluation requirements, involving 1498 stores. The score combines the daily supervision and inspection of chain headquarters, GSP certification inspection, administrative punishment and other drug quality-related information with the credit rating results of subordinate stores, and divides 100 into basic points, and forms the final score after adding and subtracting points according to the evaluation system. Those with 93 points or above are grade A (trustworthy enterprises),85-92 are grade B (basically trustworthy enterprises), and 80-84 are grade C (slightly dishonest enterprises), A score below 80 is Grade D (seriously dishonest enterprise). It is understood that the market supervision department will enter the enterprise credit rating evaluation results into the drug safety credit management system of Zhejiang Food and Drug Administration and Jinhua intelligent supervision and supervision platform to establish enterprise credit files. According to the credit rating evaluation results over the years, classified management will be carried out, and low-grade enterprises will increase the frequency of inspection. The "credit rating publicity board of drug trading enterprises" will be hung in the retail drugstore hall, and the evaluation results of the store will be publicized every year, let the people intuitively understand the credit situation of the store. At the same time, A- level enterprises are also the threshold for obtaining the qualification of designated medical insurance units, all kinds
2020
07-31
Daye Mayor to Daye Peak Research Issued "Anti-Epidemic" Donation Certificate
On the morning of March 26, Daye City Deputy Secretary, Mayor Zhou Jun and Daye City Economic and Information Bureau, Security Town and other responsible persons visited Daye Peak Cement Company to understand the epidemic prevention and control and resumption of production, and on behalf of the Daye City Charity Federation issued a certificate of donation of epidemic prevention and control materials. Accompanied by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Peak, Yuan Xianming, executive deputy general manager of Daye Peak, and others, Zhou Jun and his entourage went to the work site of Daye Peak to learn about the resumption of work and production. Zhang Fengliang introduced the progress of the upgrading and transformation of the grate cooler, the transformation of the kiln cylinder and the technical transformation of the cement mill system, and made a detailed report on the production and technical transformation organization of the enterprise during the epidemic, and expressed his gratitude to Daye City and Baoan Town for their help to Daye Peak during this period. Mayor Zhou Jun spoke highly of the production and technological transformation organization during the Daye peak epidemic, believing that this is a model of combining epidemic prevention and control with enterprise production and technological transformation organization. At the same time, Zhou Jun expressed his affirmation and gratitude to Daye Peak for donating money and goods to Daye City in the first time after the outbreak of the epidemic, and issued a donation certificate and a letter of thanks on behalf of the Daye City Charity Federation. Hubei Province epidemic prevention and control headquarters has recently issued a step-by-step "unsealing" notice in Hubei Province, how to fully resume work and production as soon as possible is an important issue facing Daye peak. Zhang Fengliang reported to Zhou Jun and his party on the current practical difficulties. Mayor Zhou Jun asked
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-30